Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22894015 | 0.93 | TDP1 (0.33) | TDP1L3MBTL1NPC1RAB9ASIRT2 | |
| SCHEMBL22894101 | 0.92 | L3MBTL1 (0.36) | TDP1L3MBTL1NPC1RAB9ASIRT2 | |
| SCHEMBL22893957 | 0.90 | TDP1 (0.32) | TDP1L3MBTL1 | |
| SCHEMBL22893955 | 0.89 | ALDH1A1 (0.33) | TDP1L3MBTL1KDM4EALDH1A1MAPT | |
| SCHEMBL18877099 | 0.89 | ALDH1A1 (0.41) | TDP1L3MBTL1KDM4EALDH1A1MAPT | |
| SCHEMBL22893841 | 0.89 | L3MBTL1 (0.33) | TDP1L3MBTL1KDM4EALDH1A1MAPT | |
| SCHEMBL22894016 | 0.87 | — | — | |
| SCHEMBL22893802 | 0.87 | NPC1 (0.36) | TDP1L3MBTL1NPC1RAB9ASIRT2 | |
| SCHEMBL22894104 | 0.86 | L3MBTL1 (0.36) | TDP1L3MBTL1NPC1RAB9ASIRT2 | |
| SCHEMBL22894065 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210013411-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210013411-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, CYP1A1, CYP1B1 | TDP1 2654/4885L3MBTL1 1367/4885NPC1 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.